685.00p+35.00 (+5.38%)16 Sep 2021, 14:00
Find out how to deal online from £1.50 in a SIPP, ISA or Dealing account.
Jump to:

4Basebio PLC Fundamentals

Company Name4Basebio PLCLast Updated2021-09-16
IndustryBiotechnologySectorHealthcare
Shares in Issue12.317 mMarket Cap£84.37 m
PE Ratio0.00Dividend per Share0
Dividend Yield0Dividend Cover0
EPS-£0.06EPS Growth (%)0
PEG0DPS Growth (%)0
Debt Ratio0.1711Debt Equity Ratio0
Asset Equity Ration/aCash Equity Ration/a
Quick Ratio19.0635Current Ratio20.05
Price To Book Value5.4585ROCE0

4Basebio PLC Dividends

TypeEx-DatePay DateCurrencyNet DividendYear Total

4Basebio PLC Company Financials

Assets20202019
Tangible Assets£1.48 m£77,000.00
Intangible Assets£785,000.00£450,000.00
Investments00
Total Fixed Assets£2.30 m£557,000.00
Stocks£131,000.00£102,000.00
Debtors£39,000.00£77,000.00
Cash & Equivalents£15.00 m£80,000.00
Other Assets00
Total Assets£17.81 m£1.16 m
Liabilities20202019
Creditors within 1 year£813,000.00£566,000.00
Creditors after 1 year£1.54 m£2.48 m
Other Liabilities00
Total Liabilities£2.35 m£3.04 m
Net assets£15.46 m-£1.89 m
Equity20202019
Called up share capital£11.13 m£6.36 m
Share Premium£706,000.000
Profit / Loss-£716,000.00-£529,000.00
Other Equity£15.46 m-£1.89 m
Preference & Minorities00
Total Capital Employed£15.46 m-£1.89 m
Ratios20202019
Debt Ratio£0.080
Debt-to-Equity£0.080
Assets / Equityn/an/a
Cash / Equityn/an/a
EPS-£0.06-£0.03
Cash Flow20202019
Cash from operating activities-£1.02 m-£269,000.00
Cashflow before financing£13.40 m£218,000.00
Increase in Cash£14.85 m£16,000.00
Income20202019
Turnover£462,000.00£202,000.00
Cost of sales£393,000.00£335,000.00
Gross Profit£69,000.00-£133,000.00
Operating Profit-£622,000.00-£420,000.00
Pre-Tax profit-£716,000.00-£529,000.00

4Basebio PLC Company Background

SectorHealthcare
Activities4basebio PLC is a life sciences group focused on therapeutic DNA for gene therapies and DNA vaccines and providing solutions for effective and safe delivery of these DNA based products to patients. Its country of operation is the UK. It isengaged in the manufacturing and supply of high purity, synthetic DNA for research, therapeutic and pharmacological use. The principal objective of 4bb is to validate and scale its DNA synthesis process to manufacture Good Manufacturing Practice grade DNA, suitable for use in gene therapies and DNA vaccines.
Latest Interim Date21 Sep 2021
Latest Fiscal Year End Date3 Jun 2021

4Basebio PLC Directors

AppointedNamePosition
2021-02-12Mr. Timothy Paul McCarthyNon-Executive Director,Chairman
2021-02-12Dr. Joseph M. FernandezNon-Executive Director
2021-02-12Mr. Hansjorg PlaggemarsNon-Executive Director
2021-07-01Dr. Heikki LanckrietExecutive Director,Chief Executive Officer
2021-02-12Mr. David John RothExecutive Director,Chief Financial Officer and Company Secretary

4Basebio PLC Contact Details

Company Name4basebio PLC
Address25 Norman Way, Over, Cambridge, CB24 5QE
Telephone+44 1223967943
Websitehttps://www.4basebio.com

4Basebio PLC Advisors